我要投票 护佑在医疗用品行业中的票数:5
· 外 推 电 报 ·
2024-11-22 17:35:51 星期五

【护佑是哪个国家的品牌?】

护佑是什么牌子?「护佑」是 扬子江药业集团有限公司 旗下著名品牌。该品牌发源于江苏省泰州市,由创始人徐镜人在2001-03-27期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

创建于1971年,拥有中西药并举,处方药与非处方药并重的产品体系,产学研/科工贸一体化的创新型医药企业集团


扬子江药业集团创建于1971年,是一家跨地区、产学研相结合、科工贸一体化的国家大型医药企业集团。集团总部位于江苏省泰州市,现有员工15000人,总占地面积300多万平方米。旗下15家成员公司分布泰州、北京、上海、南京、广州、成都、苏州、常州等地;营销网络覆盖除台湾以外的全国各省、市、自治区。

扬子江药业集团把研发创新作为企业发展战略基点,致力于国家一类新药和创新药物的研发。集团坚持不懈走创新之路,在新药研发上,全面推进“三药并举”战略,以每年按销售额3~4%比例投入新药研发,抢占科技制高点,引进具有国际视野的高端研发创新人才,建立国际化研发体系。目前在研的化学创新药、仿制药、中药和生物药达100多个,确保了短期、中期和长期产品研发有序进行。经过多年的积累和创新,产品体系覆盖10多个领域、10多种剂型、200多个品规。集团一直以市场为导向,研发产品以抗感染、心脑血管、消化系统为主,并积极开拓其它具有增长潜力的用药市场,形成“研发一批、生产一批、储备一批”的产品梯队,有力保证了企业的持续健康发展。

集团根据中医泰斗董建华院士等名老中医的验方,相继成功研发并上市胃苏颗粒、荜铃胃痛颗粒、蓝芩口服液、双花百合片、香芍颗粒、百乐眠胶囊、黄芪精口服液、柴芩清宁胶囊、青乳消颗粒、补肾润肺口服液、神曲消食口服液等一大批疗效独特的中药精品,为无数患者送去健康福音。正在建设的龙凤堂中药项目,将致力于药材自动化前处理——智能投料——原辅料、成品无人输送——机器人码垛——自动控温立体高架库储存等技术攻尖,全力打造现代化中药智能工厂。

集团发展不忘回报社会,多年来在赈灾、扶贫、拥军、助学以及各种人道主义救助活动中始终走在全社会的前列。集团至今连续16多年资助“中华医学科技奖”评选,鼎力支持祖国医学科技进步。汶川大地震发、天津港爆炸、盐城龙卷风灾害发生后,扬子江在第一时间捐赠款物,奉献爱心。

面向未来,奋进中的扬子江药业集团以振兴民族医药为己任,怀着科学、严谨、负责的态度,竭诚为全人类的健康服务。


英文翻译:Founded in 1971, Yangzijiang Pharmaceutical Group, an innovative pharmaceutical enterprise group with the integration of production, research, science, industry and trade, is a large-scale national pharmaceutical enterprise group with the integration of science, industry and trade and the combination of production, research and research. Headquartered in Taizhou City, Jiangsu Province, the group has 15000 employees and covers an area of more than 3 million square meters. Its 15 member companies are distributed in Taizhou, Beijing, Shanghai, Nanjing, Guangzhou, Chengdu, Suzhou, Changzhou and other places; the marketing network covers all provinces, cities and autonomous regions except Taiwan. Yangzijiang Pharmaceutical Group takes R & D and innovation as the strategic basis of enterprise development, and is committed to the R & D of national first-class new drugs and innovative drugs. The Group continues to take the road of innovation. In terms of new drug research and development, the group comprehensively promotes the strategy of "three drugs simultaneously". It invests in new drug research and development at the proportion of 3-4% of sales every year, seizes the commanding point of science and technology, introduces high-end R & D and innovation talents with international vision, and establishes an international R & D system. At present, more than 100 chemical innovative drugs, generic drugs, traditional Chinese medicine and biological drugs are under research, ensuring the orderly development of short-term, medium-term and long-term products. After years of accumulation and innovation, the product system covers more than 10 fields, more than 10 dosage forms and more than 200 product specifications. The group has always been market-oriented. Its R & D products mainly focus on anti infection, cardio cerebrovascular and digestive system, and actively explore other drug markets with growth potential, forming a product echelon of "R & D, production and storage", which effectively ensures the sustainable and healthy development of the enterprise. The group has successfully developed and listed a large number of excellent TCM products with unique curative effects, such as Weisu granule, bieling Weitong granule, Lanqin oral liquid, Shuanghua Lily tablet, Xiangshao granule, bailemining capsule, Huangqi essence oral liquid, chaiqinqingning capsule, qingruxiao granule, Bushen Runfei oral liquid, Shenqu Xiaoshi oral liquid, according to the prescription of famous old TCM, such as academician Dong Jianhua, the leader of traditional Chinese medicine Countless patients sent health gospel. The longfengtang traditional Chinese medicine project under construction will focus on the technology of automatic pre-processing of traditional Chinese Medicine - Intelligent feeding - raw and auxiliary materials, unmanned transportation of finished products - robot stacking - automatic temperature control three-dimensional elevated warehouse storage, and strive to build a modern intelligent factory of traditional Chinese medicine. The development of the group does not forget to repay the society, and it has always been in the forefront of the whole society in disaster relief, poverty alleviation, supporting the army, education and various humanitarian relief activities for many years. The group has supported the selection of "Chinese medical science and Technology Award" for more than 16 years in a row, making great efforts to support the progress of medical science and technology in China. After the Wenchuan earthquake, Tianjin Port explosion and Yancheng tornado disaster, the Yangtze River donated money and goods for the first time. Facing the future, the striving Yangtze River Pharmaceutical Group takes the rejuvenation of national medicine as its own duty, with a scientific, rigorous and responsible attitude, and wholeheartedly serves the health of all mankind.

本文链接: https://www.waitui.com/brand/4682ce224.html 联系电话:052386961999

千城特选小程序码

7×24h 快讯

私募购买年内上市ETF近30亿份

私募排排网统计数据显示,截至11月22日,共有126家私募证券管理人旗下产品进入到107家年内上市ETF前十大持有人名单中,合计持有份额达29.57亿份。(界面)

2小时前

外交部:进一步扩大免签国家范围并优化入境政策

36氪获悉,据外交部领事司,为进一步便利中外人员往来,中方决定扩大免签国家范围,自2024年11月30日起至2025年12月31日,对保加利亚、罗马尼亚、克罗地亚、黑山、北马其顿、马耳他、爱沙尼亚、拉脱维亚、日本持普通护照人员试行免签政策。此外,中方决定同步优化入境政策,将交流访问纳入免签事由,将免签停留期限自现行15日延长至30日。自2024年11月30日起,包括上述9国在内的38个免签国家持普通护照人员来华经商、旅游观光、探亲访友、交流访问、过境不超过30天,可免办签证入境。不符合免签条件人员仍需在入境前办妥来华签证。

2小时前

中国汽车流通协会:预计11月狭义乘用车零售市场约为240万辆

36氪获悉,据中国汽车流通协会,最新调研结果显示,11月月中整体车市折扣率约为24.1%,环比上月基本持平,终端优惠及促销政策力度无明显变化。零售量占总市场近八成的头部厂商本月零售目标环比增幅约6.5%,初步推算本月狭义乘用车零售总市场规模约为240.0万辆左右,同比去年增长15.4%,环比上月增长6.1%,新能源零售预计可达128.0万,渗透率约53.3%。

2小时前

越南电动车商VinFast母公司成立机器人研发应用企业VinRobotics

当地时间11月20日,越南电动车商VinFast母公司Vin集团宣布成立“VinRobotics机器人研发与应用股份公司”,法定资本为10万亿越南盾(约合4000万美元)。Vin集团持有新公司51%的股份,Vin集团创始人范日旺持股39%。(界面)

2小时前

康为世纪:幽门螺杆菌耐药基因检测试剂盒获得III类医疗器械注册证

36氪获悉,康为世纪发布公告,全资子公司健为诊断自主研发生产的幽门螺杆菌耐药基因检测试剂盒(基于粪便样本)收到国家药品监督管理局颁发的III类《医疗器械注册证》。

2小时前

本页详细列出关于天佑的品牌信息,含品牌所属公司介绍,天佑所处行业的品牌地位及优势。
咨询